Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

The net clinical benefit of warfarin anticoagulation in atrial fibrillation.

Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS.

Ann Intern Med. 2009 Sep 1;151(5):297-305.

2.

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.

Renda G, di Nicola M, De Caterina R.

Am J Med. 2015 Sep;128(9):1007-14.e2. doi: 10.1016/j.amjmed.2015.03.034. Epub 2015 Apr 22.

PMID:
25910790
3.

Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE.

JAMA. 2003 Nov 26;290(20):2685-92.

PMID:
14645310
4.

Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong.

Siu CW, Lip GY, Lam KF, Tse HF.

Heart Rhythm. 2014 Aug;11(8):1401-8. doi: 10.1016/j.hrthm.2014.04.021. Epub 2014 Apr 15.

PMID:
24747420
5.

Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation.

Siu CW, Tse HF.

Circ Arrhythm Electrophysiol. 2014 Apr;7(2):300-6. doi: 10.1161/CIRCEP.113.000858. Epub 2014 Mar 7.

6.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
7.

Summaries for patients. Net benefit of warfarin in atrial fibrillation.

[No authors listed]

Ann Intern Med. 2009 Sep 1;151(5):I36. No abstract available.

PMID:
19721014
8.

Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.

Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB.

J Am Coll Cardiol. 2014 Dec 16;64(23):2471-82. doi: 10.1016/j.jacc.2014.09.051.

9.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators.

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
10.

Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation.

Chan PH, Huang D, Hai JJ, Li WH, Yin LX, Chan EW, Wong IC, Lau CP, Chiang CE, Zhu J, Tse HF, Siu CW.

Heart Rhythm. 2016 Feb;13(2):366-73. doi: 10.1016/j.hrthm.2015.09.015. Epub 2015 Sep 21.

PMID:
26392326
11.

Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.

Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1142-7. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.001. Epub 2013 Nov 1.

PMID:
24189454
12.

A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study.

Azoulay L, Dell'Aniello S, Simon TA, Langleben D, Renoux C, Suissa S.

BMC Cardiovasc Disord. 2012 Jun 26;12:49. doi: 10.1186/1471-2261-12-49.

13.

Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.

Mercaldi CJ, Ciarametaro M, Hahn B, Chalissery G, Reynolds MW, Sander SD, Samsa GP, Matchar DB.

Stroke. 2011 Jan;42(1):112-8. doi: 10.1161/STROKEAHA.110.592907. Epub 2010 Dec 9.

14.

Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.

Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O.

Curr Med Res Opin. 2005 Oct;21(10):1583-94.

PMID:
16238898
15.

Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study.

Friberg L, Rosenqvist M, Lip GY.

Circulation. 2012 May 15;125(19):2298-307. doi: 10.1161/CIRCULATIONAHA.111.055079. Epub 2012 Apr 18.

16.

The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.

Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ.

J Manag Care Pharm. 2013 May;19(4):302-16.

17.

Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation.

Nielsen PB, Larsen TB, Skjøth F, Lip GY.

JAMA Intern Med. 2017 Apr 1;177(4):563-570. doi: 10.1001/jamainternmed.2016.9369.

PMID:
28241151
18.

Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.

Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, Singer DE.

J Am Geriatr Soc. 2006 Aug;54(8):1231-6.

19.

Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.

Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P.

Circulation. 2004 Oct 19;110(16):2287-92. Epub 2004 Oct 11.

20.

Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage.

Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA.

Circulation. 2016 Apr 19;133(16):1540-7. doi: 10.1161/CIRCULATIONAHA.115.019794. Epub 2016 Mar 11.

Supplemental Content

Support Center